Characteristics of NPM1-mutated patients with AML at diagnosis
| Total cohort, n = 252 . | . | . |
|---|---|---|
| Sex | Female, n = 132 | Male, n = 120 |
| Age, y | Median: 58.9 | Range: 20.1-79.3 |
| WBC, ×109/L | Median: 22.4 | Range: 0.5-300.0 |
| Platelets, ×109/L | Median: 72.5 | Range: 9.0-766.0 |
| De novo | n = 238 | 94.4% |
| After MDS (s-AML) | n = 8 | 3.2% |
| After treatment of a previous malignancy (t-AML) | n = 6 | 2.3% |
| FAB subtype | ||
| AML M0 | n = 5 | 2.0% |
| AML M1 | n = 55 | 21.9% |
| AML M2 | n = 63 | 25.1% |
| AML M4 | n = 70 | 27.9% |
| AML M5 | n = 32 | 12.7% |
| AML M6 | n = 7 | 2.8% |
| AML M7 | n = 1 | 0.4% |
| Not specified | n = 19 | 7.2% |
| Cytogenetics available | n = 247 | 98.0% |
| Normal karyotype | n = 205 | 83.0% |
| Trisomy 4 | n = 5 | 2.0% |
| Trisomy 8 | n = 6 | 2.4% |
| Trisomy 21 | n = 2 | 0.8% |
| Multiple trisomies | n = 6 | 2.4% |
| -7/7q- | n = 2 | 0.8% |
| -Y | n = 4 | 1.6% |
| Del(3p) | n = 1 | 0.4% |
| Del(9q) | n = 4 | 1.6% |
| Del(20q) | n = 2 | 0.8% |
| Nonrecurrent translocations | n = 10 | 4.1% |
| FLT3-LM (available: n = 251) | Mutated: 95 (37.8%) | Wild-type: 156 (62.2%) |
| FLT3-TKD (available: n = 246) | Mutated: 17 (6.9%) | Wild-type: 229 (93.1%) |
| Total cohort, n = 252 . | . | . |
|---|---|---|
| Sex | Female, n = 132 | Male, n = 120 |
| Age, y | Median: 58.9 | Range: 20.1-79.3 |
| WBC, ×109/L | Median: 22.4 | Range: 0.5-300.0 |
| Platelets, ×109/L | Median: 72.5 | Range: 9.0-766.0 |
| De novo | n = 238 | 94.4% |
| After MDS (s-AML) | n = 8 | 3.2% |
| After treatment of a previous malignancy (t-AML) | n = 6 | 2.3% |
| FAB subtype | ||
| AML M0 | n = 5 | 2.0% |
| AML M1 | n = 55 | 21.9% |
| AML M2 | n = 63 | 25.1% |
| AML M4 | n = 70 | 27.9% |
| AML M5 | n = 32 | 12.7% |
| AML M6 | n = 7 | 2.8% |
| AML M7 | n = 1 | 0.4% |
| Not specified | n = 19 | 7.2% |
| Cytogenetics available | n = 247 | 98.0% |
| Normal karyotype | n = 205 | 83.0% |
| Trisomy 4 | n = 5 | 2.0% |
| Trisomy 8 | n = 6 | 2.4% |
| Trisomy 21 | n = 2 | 0.8% |
| Multiple trisomies | n = 6 | 2.4% |
| -7/7q- | n = 2 | 0.8% |
| -Y | n = 4 | 1.6% |
| Del(3p) | n = 1 | 0.4% |
| Del(9q) | n = 4 | 1.6% |
| Del(20q) | n = 2 | 0.8% |
| Nonrecurrent translocations | n = 10 | 4.1% |
| FLT3-LM (available: n = 251) | Mutated: 95 (37.8%) | Wild-type: 156 (62.2%) |
| FLT3-TKD (available: n = 246) | Mutated: 17 (6.9%) | Wild-type: 229 (93.1%) |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; and WBC, white blood cell count.